ReviewCurrent cardiology reports2019
Endomyocardial Fibrosis: an Update After 70 Years.
Review in Current cardiology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A Narrative Review on Endomyocardial Fibrosis: Unraveling an Under-Recognized Tropical Heart Disease.Cureus · 2025Review
- Endomyocardial fibrosis: recent advances and future therapeutic targets.Nature reviews. Cardiology · 2025Review
- Multimodality imaging analysis of the spectrum of endomyocardial fibrosis involvement in a clinical case series.European heart journal. Case reports · 2025Article
- Rheumatic Heart Disease and Endomyocardial Fibrosis: A Complex Novel Case of Heart Failure.JACC. Case reports · 2024Article
- Prevalence of Hypertrophic Cardiomyopathy and ALMS1 Variant in Sphynx Cats in New Zealand.Animals : an open access journal from MDPI · 2024Article
- Article
- [Endomyocardial fibrosis: case report].Archivos de cardiologia de Mexico · 2024Article
- Insulin-like growth factor binding protein 2: a core biomarker of left ventricular dysfunction in dilated cardiomyopathy.Hereditas · 2023Article
- Interplay between BMP2 and Notch signaling in endothelial-mesenchymal transition: implications for cardiac fibrosis.Stem cell investigation · 2023Article
- Endomyocardial fibrosis in a non-tropical patient who presented with chest pain mimicking ACS and left ventricular thrombus, case report.Clinical case reports · 2022Article
- The position of geochemical variables as causal co-factors of diseases of unknown aetiology.SN applied sciences · 2022Review
- Endomyocardial Fibrosis as a Rare Cause of Heart Transplantation and its Association with Thrombophilia: A Case Report.Arquivos brasileiros de cardiologia · 2022Article
- Overview of Restrictive Cardiomyopathies.Methodist DeBakey cardiovascular journal · 2022Review
- Trends in Annual Incidence Rates of Newly Diagnosed Endomyocardial Fibrosis Cases at the Uganda Heart Institute: A 14-Year Review.Frontiers in cardiovascular medicine · 2022Article
- Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward.Frontiers in cardiovascular medicine · 2022Review
- Multimodality Imaging in Endomyocardial Fibrosis: An Unusual Etiology of Heart Failure.CASE (Philadelphia, Pa.) · 2021Article
- Article
- Review
- Point-of-Care Ultrasound: Applications in Low- and Middle-Income Countries.Current anesthesiology reports · 2021Review
- Idiopathic endomyocardial fibrosis in a Western European: a case report.European heart journal. Case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims at highlighting the need to better understand the pathogenesis and natural history of endomyocardial fibrosis when set against its changing endemicity and disease burden, improvements in diagnosis, and new options for clinical management. RECENT
findingsProgress in imaging diagnostic techniques and availability of new targets for drug and surgical treatment of heart failure are contributing to earlier diagnosis and may lead to improvement in patient survival. Endomyocardial fibrosis was first described in Uganda by Davies more than 70 years ago (1948). Despite its poor prognosis, the etiology of this neglected tropical restrictive cardiomyopathy still remains enigmatic nowadays. Our review reflects on the journey of scientific discovery and construction of the current guiding concepts on this mysterious and fascinating condition, bringing to light the contemporary knowledge acquired over these years. Here we describe novel tools for diagnosis, give an overview of the improvement in clinical management, and finally, suggest research themes that can help improve patient outcomes focusing (whenever possible) on novel players coming into action.
Indexed as
Identifiers
31758352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.